DDInter224 DDInter1676
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bosutinib {u} (Compound) resembles {v} (Compound) Gefitinib
Bosutinib {u} (Compound) binds {v} (Gene) PTK2
Bosutinib {u} (Compound) upregulates {v} (Gene) HSD17B7
Bosutinib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Bosutinib {u} (Compound) downregulates {v} (Gene) COTL1
Bosutinib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Bosutinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Famotidine
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium carbonate
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Bosutinib (Compound) resembles Gefitinib (Compound)
Bosutinib (Compound) binds PTK2 (Gene)
Bosutinib (Compound) upregulates HSD17B7 (Gene)
Bosutinib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Bosutinib (Compound) downregulates COTL1 (Gene)
Bosutinib (Compound) causes Cardiac disorder (Side Effect)
Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen